What is PLX's market cap?

$216.74M, based on the Nov 4 close of $2.69.

What is PLX's P/E ratio?

11.4× trailing-twelve-month earnings of $18.95M.

Does Protalix BioTherapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of PLX is sold short?

3.5M shares, 4.7% of float, as of Oct 15, 2026.

What sector is PLX in?

Healthcare, in the Biotechnology industry.

NYSE American · PLXHealthcareBiotechnology

Protalix BioTherapeutics, Inc. Common Stock (PLX)

$2.69+3.07%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$2.61▲ 9.21% in range

Nov 3, 2025Low $1.67 · High $3.15Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Protalix BioTherapeutics closed at $2.69 on Nov 4, up 3.07%, 14.6% below its 52-week closing high. Volume of 870.8K shares was 1.20× its 20-day average (close to normal).

Split-adjusted performance: -1.5% over one month, +33.2% over six months, +12.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $19.90M, up 27.1% from a year earlier, with a net margin of 19.0%.

Short interest was 3.5M shares at the Oct 15 settlement, up 15.4% from the prior report (4.7% of float, 3.3 days to cover).

Market cap$216.7M80.6M shares

Revenue · quarter$19.9M+27.1% YoY

Diluted EPS$0.05—

P/E · TTM11.4×P/S 2.7×

Net margin19.0%Gross 61.0%

Dividend yieldNone

52-week range1.67 – 3.15−14.6% from high

Volume870.8K1.20× 20-day avg

Volatility · 60d45.0%Annualised

Short % of float4.7%3.3 days to cover

Net cash$40.7MCash $40.7M

Next earnings—Not scheduled

Split-adjusted performance

1W +3.9%1M −1.5%3M +10.2%6M +33.2%YTD +49.4%1Y +12.6%3Y +80.5%5Y +142.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum84

Revenue growth68

Net margin81

Value (low P/E)77

Size45

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →

Shares short3.5M+15.4% vs prior

Days to cover3.3Settled Oct 15

% of float4.7%

Short vol. 10d64.4%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
PLXProtalix BioTherapeutics	$2.69	+3.07%	+33.2%	+27.1%	19.0%	11.4	$216.7M
PALIPalisade Bio	$1.25	+1.63%	−37.5%	—	−2114.8%	—	$217.8M	Compare
IKTInhibikase Therapeutics	$1.57	+5.74%	−22.1%	—	—	—	$218.4M	Compare
DTILPrecision BioSciences	$8.12	+16.50%	+8.0%	−100.0%	—	—	$224.1M	Compare
ARTVArtiva Biotherapeutics	$4.22	+0.48%	−65.9%	—	—	—	$206.3M	Compare
PROKProKidney	$1.12	+4.67%	−42.9%	−32.1%	−18948.0%	—	$234.1M	Compare
CABACabaletta Bio	$1.42	0.00%	−61.9%	—	—	—	$240.8M	Compare
FATEFate Therapeutics	$2.09	+2.45%	−8.7%	+9.2%	−1448.6%	—	$250.4M	Compare
IVVDInvivyd	$0.6336	+8.96%	−56.6%	+21.2%	−310.8%	—	$186.8M	Compare

News about Protalix BioTherapeutics

All news →

Protalix (PLX) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 19, 2026▲ Positive Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)GlobeNewswire Inc. · Mar 9, 2026▲ Positive

Quick answers

What does Protalix BioTherapeutics do?: Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner.
What is PLX's market cap?: $216.74M, based on the Nov 4 close of $2.69.
What is PLX's P/E ratio?: 11.4× trailing-twelve-month earnings of $18.95M.
Does Protalix BioTherapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of PLX is sold short?: 3.5M shares, 4.7% of float, as of Oct 15, 2026.
What sector is PLX in?: Healthcare, in the Biotechnology industry.

About Protalix BioTherapeutics

Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

HQ: Hackensack, NJ226 employeesListed Jan 2, 1996protalix.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology